All In Biotech

Drug Trial Radar · NCT06822426

Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)

A Phase 3, Prospective, Multicenter, Double-Blind, Randomized, Controlled, Adaptive Study To Demonstrate The Safety And Efficacy Of DEFENCATH® In Reducing Central Line-Associated Bloodstream Infections (CLABSIs) In Adult And Adolescent Participants Receiving Total Parenteral Nutrition (TPN) Via Central Venous Catheter (CVC)

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

May 14, 2025

Primary completion

Jan 2028

Study completion Jan 2028

Sponsor

Lead sponsor
CorMedix TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult and adolescent participants receiving home Total Parenteral Nutrition (TPN) via Central Venous Catheter (CVC) compared with heparin.

Conditions

  • Central Line Associated Blood Stream Infections (CLABSI)

Interventions

  • (taurolidine and heparin) catheter lock solutionDrug

    for central venous catheter installation use

  • HeparinDrug

    Heparin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison between treatment groups of proportion of participants who experience a Central Line-Associated Bloodstream Infections (CLABSI) within 12 months of the start of the studyTime frame: Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California Los Angeles

    Los Angeles, California · Recruiting

  • MedStar Health Research Institute

    Washington D.C., District of Columbia · Recruiting

  • Bioresearch Partner

    Doral, Florida · Recruiting

  • Emory University Hospital - GCRC

    Atlanta, Georgia · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • Loyola University Medical Center

    Maywood, Illinois · Recruiting

  • University of Iowa Health Care

    Iowa City, Iowa · Recruiting

  • Johns Hopkins Clinical Research Unit

    Baltimore, Maryland · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • NYU Grossman School of Medicine

    New York, New York · Not yet recruiting

  • Mount Sinai Medical Center

    New York, New York · Recruiting

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

  • Duke University Hospital

    Durham, North Carolina · Withdrawn

  • Cleveland Clinic Foundation

    Cleveland, Ohio · Recruiting

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Rhode Island Hospital

    Providence, Rhode Island · Recruiting

  • Vanderbilt Center for Human Nutrition

    Nashville, Tennessee · Recruiting

  • Alchemi - Sugarland

    Sugarland, Texas · Recruiting

  • Hacettepe University Hospitals

    Altındağ, Ankara, Turkey (Türkiye) · Recruiting

  • Ankara University Ibni Sina Research and Application Hospital

    Çankaya, Ankara, Turkey (Türkiye) · Recruiting

  • Ankara Bilkent City Hospital

    Çankaya, Ankara, Turkey (Türkiye) · Recruiting

  • Hacettepe University Hospitals

    Yenimahalle, Ankara, Turkey (Türkiye) · Recruiting

  • Istanbul University Faculty of Medicine, Capa State Hospital

    Istanbul, Istanbul, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.